Noetik Secures $40M Series A to Advance Precision Cancer Therapies
Noetik, an AI-driven biotech firm using self-supervised machine learning and high-throughput spatial data to create cutting-edge cancer therapies, has announced the successful closure of an oversubscribed $40 million Series A funding round. Noetik, an AI-native biotech company focused on precision…
Kiyatec Publishes Study on 3D Predict™ for High-Grade Glioma
Kiyatec, a leader in functional precision oncology, has announced the publication of a key study in Scientific Reports showcasing the benefits of the 3D Predict Glioma test for high-grade glioma (HGG) patients. Titled “Functional Prediction of Response to Therapy Prior…
Jupiter Endovascular Gets FDA Nod for Vertex Pulmonary Embolectomy System Pivotal Study
Jupiter Endovascular, Inc., a medical tech innovator specializing in advanced endovascular procedures through Endoportal Control™, has received FDA approval for its Investigational Device Exemption application. This approval clears the way for the SPIRARE II U.S. pivotal study (NCT06576427) to advance,…
CharmHealth Announces 2024 Innovation Challenge Winners
CharmHealth, a leader in healthcare technology solutions, has unveiled the winners of its 2024 Innovation Challenge. Entering its fourth year, the challenge aims to discover groundbreaking ideas poised to transform healthcare systems and processes. This year’s CharmHealth Innovation Challenge saw…
Renata Medical’s Minima Growth Stent Gains FDA Approval for Aortic Coarctation and Pulmonary Artery Stenosis
Renata Medical has announced that the U.S. Food and Drug Administration (FDA) has approved its innovative Minima Growth Stent, designed specifically for neonates, infants, and young children. This unique stent is engineered to be re-expanded as the child grows, offering…
ASM Announces Retirement of Founder and CEO Trung Phan
Applied Statistics & Management Inc. (ASM), a top provider of medical staff credentialing and privileging solutions, has announced the retirement of its founder, President, and CEO, Trung Phan. Trung Phan will step down from his role on August 30, 2024,…
RebrAIn Secures Second FDA Clearance for Enhancing Targeting in Neurosurgery
RebrAIn, a leader in precision neuro-surgery platforms, has secured its second FDA 510(k) clearance for its OptimMRI software. The latest version includes a machine learning model designed to aid in targeting the infero-lateral part of the VIM for lesioning techniques…
Median Technologies’ eyonis™ LCS Lung Cancer Diagnostic Hits All Study Endpoints
Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible) announced that its AI-powered diagnostic tool, eyonis™ LCS, met the primary and all secondary endpoints in the REALITY study, the first of two pivotal trials required for marketing approval in the U.S. and…
Kaneka Completes New Medical Device Plant in Hokkaido
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO: 4118) has opened its Tomatoh Manufacturing Site in the Tomakomai Tobu Area of Hokkaido, marking its seventh domestic business location and the first new site in 54 years. An opening ceremony…
Alnylam Shares HELIOS-B Phase 3 Results on Vutrisiran for ATTR Amyloidosis at ESC Congress
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The data were presented at…
Novotech Reaccredited as Employer of Choice for Gender Equality
Novotech, a global full-service clinical Contract Research Organization (CRO), is pleased to announce its renewal as a Workplace Gender Equality Agency (WGEA) Employer of Choice for Gender Equality (EOCGE) for 2024. This accolade highlights Novotech’s ongoing dedication to maintaining an…
Allurion Publishes Data Showing Continued Weight Loss After One Year on Its Program
Allurion Technologies, Inc. (NYSE: ALUR) has announced new study results showing an average weight reduction of 10.5% at four months, improving to 13.7% at one year with the Allurion Program. This data highlights that not only can weight loss be…